NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2015, the company’s fiscal first quarter. The filing was signed November 9, 2015. NanoViricides is a pre-revenue antiviral drug developer; its candidates remain in preclinical development.
Financial performance and position
| Metric | Three months ended Sept. 30, 2015 | Three months ended Sept. 30, 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.282 million | $811,107 |
| General and administrative expense | $942,979 | $876,026 |
| Total operating expenses / operating loss | $2.225 million | $1.687 million |
| Net income (loss) | $(1.307) million | $851,697 |
| Basic and diluted earnings (loss) per share | $(0.02) | $0.02 |
| Net cash used in operating activities | $1.654 million | $1.696 million |
| Capital expenditures | $333,664 | $562,512 |
There is no meaningful revenue or operating margin because the company has no sales. The 2015 quarter’s reported other income, net, of $918,097 included a $1.488 million noncash gain from changes in derivative fair values; it partly offset operating and financing expenses. Interest expense was $245,000 and debt-discount amortization was $333,710. No income tax provision was recorded.
At September 30, 2015, cash and cash equivalents were $29.480 million, down $1.987 million from June 30. Current assets were $29.644 million and current liabilities $983,091. Total assets were $42.299 million; total liabilities were $11.587 million; stockholders’ equity was $30.712 million. Net property and equipment was $12.135 million.
Convertible debentures had $11 million in stated principal: $6 million Series B and $5 million Series C. Their combined balance-sheet carrying value, net of discounts, was approximately $7.515 million. The Series B and C debentures are owed to a company director; their principal totaled $9 million. Total derivative liabilities were $2.798 million. Accounts payable to related parties, principally TheraCour Pharma, were $738,287.
Changes versus the prior comparable period
- Net results shifted from $851,697 income to a $1.307 million loss, despite a $1.530 million smaller derivative fair-value gain than in 2014.
- R&D expense increased $470,965, which management attributed mainly to higher R&D payroll, laboratory supplies, and materials. G&A rose $66,953, primarily due to noncash stock compensation, partly offset by lower rent and other costs.
- Operating cash use was similar year over year, while capital expenditures fell by about $229,000. The prior-year quarter included $6.682 million of warrant-exercise proceeds; there were no such proceeds in the 2015 quarter.
- Cash declined from $31.468 million at June 30, 2015. Common shares outstanding increased from 57.242 million to 57.586 million during the quarter; preferred shares were also issued as compensation.
Outlook, commentary, and risks
- Management estimated that existing cash could fund operations through at least September 30, 2017 at the then-current expenditure rate. It said available funds were expected to support toxicology and efficacy work, one or possibly two regulatory applications, and initial clinical trials. These estimates rely on preliminary cost quotes and timelines; management warned that delays or higher costs could require reprioritization or additional financing.
- Management prioritized injectable FluCide for severe influenza and topical HerpeCide for herpes. Both were described as late or advanced preclinical/IND-enabling candidates. IND submissions and clinical trials were objectives, not assured outcomes. The Shelton manufacturing facility was operational, but equipment validation, process scale-up, reproducible batches, and manufacturing controls remained necessary.
- Management reported animal-study findings for FluCide and HerpeCide and described other programs, including HIVCide, DengueCide, and ocular antivirals. These are company-reported preclinical findings; none of the products was commercialized, and the filing provides no clinical efficacy evidence in humans.
- Material execution and development risks include unsuccessful studies, regulatory requirements, manufacturing validation, reliance on external collaborators and CROs, and dependence on TheraCour-licensed technology. The company reported no pending or threatened legal proceedings to its knowledge.
- Disclosure controls and internal control over financial reporting were reported ineffective because of a material weakness: insufficient personnel expertise to identify and account for non-routine transactions such as derivatives. Management said remediation initiatives had not operated long enough to demonstrate effectiveness.
- The company reported no off-balance-sheet arrangements during the nine months ended September 30, 2015. It also noted that additional capital could be needed if costs, staffing needs, or timelines exceed expectations.
Key facts for investors to verify
- Whether cash burn and development spending remain consistent with management’s stated runway through September 2017.
- Progress and actual timing of FluCide and HerpeCide IND-enabling work, manufacturing validation, and any regulatory submissions or clinical trials.
- How much of reported earnings depends on noncash derivative remeasurement, and the terms, maturity, and potential dilution or cash obligations of the Series B and C debentures and warrants.
- Related-party charges, balances, and licensing arrangements with TheraCour, including the director’s debenture holdings.
- Whether the disclosed material weakness in financial reporting is remediated and whether disclosure controls become effective.